Under the terms of the agreement, the costs of the collaboration projects will be borne 60% by Aradigm and 40% by CyDex, with third-party licensing and sales revenues to be shared in the same ratio.
“There is a lot of interest in inhalation products containing a combination of drugs as these have proven to be very popular with millions of asthma and COPD patients,” said Igor Gonda, Aradigm's president and CEO. “We are pleased to be working with CyDex – a company with an excellent track record of developing and partnering innovative pharmaceutical products.”